Aqneursa
Customize your policy alerts
Sign up for Cigna Policy IP0715 alerts
Get alerted when Policy IP0715 changes without checking for updates manually.
Monitor payer policy activity
This Cigna drug coverage policy governs prior authorization and benefit coverage for Aqneursa (levacetylleucine oral suspension). It applies to health benefit plans administered by Cigna Companies, subject to the member's specific benefit plan, applicable law, and the clinical criteria in the policy.
The initial approval duration for Niemann-Pick disease type C was changed from 6 months to 1 year.
Ataxia-Telangiectasia was added as a new FDA-approved indication with new initial- and continuation-therapy criteria.
Ataxia-Telangiectasia was removed from the Conditions Not Covered section.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.